Details for New Drug Application (NDA): 209269
✉ Email this page to a colleague
NDA 209269 describes MINOLIRA, which is a drug marketed by Epi Hlth and is included in one NDA. There is one patent protecting this drug. Additional details are available on the MINOLIRA profile page.
The generic ingredient in MINOLIRA is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
The generic ingredient in MINOLIRA is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for 209269
| Tradename: | MINOLIRA |
| Applicant: | Epi Hlth |
| Ingredient: | minocycline hydrochloride |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 209269
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 105MG BASE | ||||
| Approval Date: | May 8, 2017 | TE: | RLD: | No | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Apr 7, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 135MG BASE | ||||
| Approval Date: | May 8, 2017 | TE: | RLD: | No | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Apr 7, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
